Contributed Poster Presentations Session 1

CARDIOVASCULAR DISEASE RESEARCH
PCD1	INCORPORATING BOTH DIASTOLIC AND SYSTOLIC PRESSURES IN A MODEL OF THE BENEFITS OF ACHIEVING HYPERTENSION TREATMENT TARGETS Huse DM1, Russell MW1, Usry CA2, Hartz SC1, 1ICSL Healthcare Research, Burlington, MA, USA; 2AstraZeneca Pharmaceuticals, Wayne, PA, USA
PCD2	ASSESSING THE BURDEN OF ILLNESS IN ELDERLY VERSUS YOUNGER ACUTE CORONARY SYNDROME PATIENTS Eisenstein EL1, Peterson ED1, Shaw LK1, Hasselblad V1, Nelson CL1, Hakim Z2, Mark DB1, 1Duke Clinical Research Institute, Durham, NC, USA; 2Roche Global Pharmacoeconomic Research, Palo Alto, CA, USA
PCD3	INCIDENCE, UTILIZATION OF HEALTH CARE AND COSTS OF STROKE Wilson L1, Le K2, Nguyen C2, Tam A2, Le S2, 1Pharmaceutical Policy and Economics Department, University of California, San Francisco, CA, USA; 2School of Pharmacy, University of California, San Francisco, CA, USA
PCD4	THE IMPACT OF SECONDARY EVENTS ON THE COST OF ACUTE MYOCARDIAL INFARCTION O'Brien J, Pierce D, Caro J, Caro Research, Concord, MA, USA
PCD5	COSTS OF LEFT VENTRICULAR ASSIST DEVICE VERSUS POSITIVE INOTROPIC THERAPY AS A BRIDGE TO HEART TRANSPLANT Stanek EJ12, Loh E2, 1College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, PA, USA; 2University of Pennsylvania Medical Center, Philadelphia PA, USA
PCD6	COST ANALYSIS OF ANTIHYPERTENSIVE DRUG USE IN TURKEY Sapci H1, Bozkurt E2, Durlu T2, Kandilci B2, Ozsogut B2, Demirdamar R2, Akalin K3, Mutlugil A3, 1Numune Hospital, Ankara, Turkey; 2Faculty of Pharmacy, Hacettepe University, Ankara, Turkey; 3General Directorate of Pharmaceuticals, Ankara, Turkey
PCD7	SOCIECONOMIC EVALUATION OF CILOSTAZOL FOR THE SECONDARY PREVENTION OF CEREBRAL INFARCTION IN JAPAN Kobayashi M1, Gotoh F2, 1Crecon Research and Consulting Inc., Tokyo, Japan; 2School of Medicine, Keio University, Tokyo, Japan
PCD8	A MODEL COMPARING NITROGLYCERIN FORMULATIONS FOR ACUTE ANGINA EPISODES: ASSESSING THE ECONOMIC ISSUES Bell CF, Semroc GN, Stephens JM, Klingman D, Dever MT, PAREXEL International, Outcomes Research Group, Alexandria, VA, USA
PCD9	COST EFFECTIVENESS OF RAMIPRIL IN HYPERTENSIVE PATIENTS WITH NEPHROPATHY IN GERMANY Schädlich PK1, Brecht JG1, Huppertz E2, 1PAREXEL GmbH, InForMed Outcomes Research & Pharmacoeconomics, Berlin, Germany; 2Aventis Pharmaceuticals Deutschland GmbH, Bad Soden, Germany
PCD10	IMPACT OF NEW STATIN DOSES ON MARKET SEGMENTATION Miller JD, Russell MW, Huse DM, Hartz SC, ICSL Healthcare Research, Burlington, MA, USA
PCD11	THE COST-EFFECTIVENESS ANALYSIS AS A SUBSTANTIATION OF DIAGNOSTIC AND TREATMENT OF EARLY STAGE OF HEART FAILURE Gorokhova SG, Vorobiev PA, Moscow Medical Academy, Moscow, Russia
PCD12	SPIRONOLACTONE IN HEART FAILURE: LIFE AND COST SAVING TREATMENT IN POLAND Kuzniar J, Orlewska E, Splawinski J, Institute of Drugs, Warsaw, Poland
PCD13	COST-EFFECTIVENESS ANALYSIS OF ENALAPRIL IN THE MANAGEMENT OF CHF IN POLAND Orlewska E, Kuzniar J, Romanczuk W, Splawinski J, Institute of Drugs, Warsaw, Poland
PCD14	TREATMENT COST OF SIDE EFFECTS OF ANTIARRHYTHMIC DRUGS IN THE USA Bhattacharyya SK, Morrato EH, Procter & Gamble Pharmaceuticals, Mason, OH, USA
PCD15	HOW MEANINGFUL ARE THE CORONARY BENEFITS OF SELECTIVE ESTROGEN RECEPTOR MODULATORS? Russell MW, Huse DM, Miller JD, Hartz SC, ICSL Healthcare Research, Burlington, MA, USA
PCD16	COST-EFFECTIVENESS OF TIROFIBAN PLUS HEPARIN AS COMPARED WITH HEPARIN ONLY IN TREATING UNSTABLE ANGINA Shi L, Hay J, Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
PCD17	THE EFFECTS OF PAYOR STATUS ON PROCEDURE USE AND OUTCOMES OF PATIENTS WITH CONGESTIVE HEART FAILURE Kroch E123, Loh E3, Schwartz JS3, Shah R3, Fisher D3, 1Villanova University, Villanova, PA, USA; 2Care Management Science Corporation, Philadelphia, PA, USA; 3University of Pennsylvania, Philadelphia, PA, USA
PCD18	THE PERCEPTUAL EFFECTIVENESS INDEX: A NEW APPROACH FOR EVALUATING OUTCOMES OF ANTI-HYPERTENSIVE THERAPY Leidy NK1, Flynn J1, Zyczynski TM2, 1MEDTAP International, Inc., Bethesda, MD, USA; 2AstraZeneca, Wayne, PA, USA
PCD19	RELATIONSHIP BETWEEN DAILY DOSE FREQUENCY AND ADHERENCE TO ANTIHYPERTENSIVE PHARMACOTHERAPY: UPDATE OF A META-ANALYSIS Iskedjian M12, Einarson TR1, 1University of Toronto, Toronto, ON, Canada; 2PharmIdeas Research and Consulting Inc., Hamilton, ON, Canada
PCD20	ESTIMATING THE EFFECTS OF POLYPHARMACY ON HOSPITALIZATION IN AN ELDERLY CHF MEDICAID POPULATON Bramley T, Dickson M, Rowen R, University of South Carolina, Columbia, SC, USA
PCD21	TWO-YEAR MEDICATION COMPLIANCE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION Plante M12, Gupta A1, Bruckman D1, Mehta R1, Eagle K1, 1University of Michigan Health System, Ann Arbor, MI, USA; 2Parke-Davis, Ann Arbor, MI, USA
PCD22	THE EFFECT OF NATIONALITY ON HEALTH-RELATED QUALITY OF LIFE IN THE GUSTO-I ANGIOGRAPHIC TRIAL Coyne K1, Hill M2, Allen J2, Kim M2, Chandra N2, Ross A3, 1MEDTAP International, Bethesda, MD, USA; 2Johns Hopkins University, Baltimore, MD, USA; 3George Washington University, Washington, DC, USA
PCD23	UNADJUSTED INPATIENT COSTS AND MORTALITY FOR FOUR CEREBROVASCULAR EVENTS FOR PATIENTS TREATED AT COMMUNITY TEACHING AND NONTEACHING HOSPITALS Reed SD1, Jarvik JG2, Meyer KE3, 1Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA; 2School of Medicine, University of Washington, Seattle, WA, USA; 3HBS International, Inc., Bellevue, WA, USA
PCD24	CONJOINT ANALYSIS COMPARING PREFERENCES FOR TREATMENT OUTCOMES IN HEART FAILURE AND HEALTHY PATIENTS: LONGEVITY VERSUS SYMPTOM RELIEF Oates MB1, Stanek EJ12, McGhan WF1, DeNofrio D2, Loh E2, 1University of the Sciences, Philadelphia, PA, USA; 2University of Pennsylvania Health System, Philadelphia, PA, USA
PCD25	SYSTEMATIC REVIEW EVIDENCE ON TREATING HYPERTENSION IN OLDER ADULTS McDonagh M, Bradley M, Shirley A, Kleijnen J, NHS Centre for Reviews and Dissemination, University of York, York, UK
PCD26	A CLOSER LOOK AT HYPERTENSION PRACTICE PATTERNS AND MEDICATION COMPLIANCE Guico-Pabia CJ1, Campbell RF2, Dedeker K3, Sheffield R4, Moravec R5, Wertheimer AI1, 1Merck & Co., Inc., West Point, PA, USA; 23M Corporation, St. Paul, MN, USA; 3Preferred One PPO Network, Minneapolis, MN, USA; 4PCS Health Systems, Scottsdale, AZ, USA; 5HealthEast Care Inc., St. Paul, MN, USA
MENTAL HEALTH, MIGRAINE PAIN, AND NEUROLOGICAL DISORDER RESEARCH
PMH1	RECENT TRENDS IN THE COST OF CARE FOR PATIENTS WITH SCHIZOPHRENIA Johnstone BM1, Loosbrock DL1, Stockwell Morris L2, Gibson JP1, Barber BL1, Lichtenstein M2, Henderson S2, Dulisse BK1, 1Eli Lilly and Company, Indianapolis, IN, USA; 2Disease, Treatment and Outcomes Information Services, IMS Health, Plymouth Meeting, PA, USA
PMH2	ESTIMATED COSTS OF TREATMENT FOR BIPOLAR AFFECTIVE DISORDER IN A LARGE EMPLOYER DATABASE Johnstone BM1, Loosbrock DL1, Stockwell Morris L2, Gibson JP1, Barber BL1, Lichtenstein M2, Henderson S2, Dulisse BK3, 1Health Outcomes Evaluation Group, Eli Lilly and Company, Indianapolis, IN, USA; 2Disease, Treatment and Outcomes Information Services, IMS Health, Plymouth Meeting, PA, USA; 3Mathematical and Statistical Sciences, Eli Lilly and Company, Indianapolis, IN, USA
PMH3	ALZHEIMER'S DISEASE COST OF CARE IN MANAGED CARE Richards KM1, Shepherd MD1, Crismon ML1, Snyder EH2, 1College of Pharmacy, University of Texas at Austin, Austin, TX, USA; 2Novartis Pharmaceuticals, East Hanover, NJ, USA
PMH4	ANTIPSYCHOTIC MEDICATION TREATMENT PATTERNS AND ASSOCIATED COST OF CARE OF PATIENTS WITH SCHIZOPHRENIA Loosbrock DL1, Johnstone BM1, Stockwell Morris L2, Gibson PJ1, Barber BL1, Lichtenstein MS2, Henderson SC2, Dulisse BK3, 1Health Outcomes Evaluation Group, Eli Lilly and Company, Indianapolis, IN, USA; 2Disease, Treatment and Outcomes Information Services, IMS Health, Plymouth Meeting, PA, USA; 3Mathematical and Statistical Sciences, Eli Lilly and Company, Indianapolis, IN, USA
PMH5	THE EFFECT OF RIVASTIGMINE ON THE DIRECT AND INDIRECT COSTS OF ALZHEIMER'S DISEASE Brooks E, Deal L, Research Triangle Institute, Center for Economics Research, Research Triangle Park, NC, USA
PMH6	PHARMACOECONOMIC ANALYSES OF DEPOT NEUROLEPTIC TREATMENT IN NATURAL SETTING Gurovich I1, Kobina S2, Lyubov E1, Litvischenko Y2, Shmukler A1, 1Moscow Research Institute of Psychiatry of the Russian Federation, Moscow, Russia; 2Aventis Pharmaceuticals, Inc., Moscow, Russia
PMH7	COST EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN CHRONIC SCHIZOPHRENIA Karki SD1, Bellnier TJ1, Hager EP2, 1SUNY, School of Pharmacy, Buffalo, NY, USA; 2Rochester Community Individual Practice Association, Rochester, NY, USA
PMH8	COST-EFFECTIVENESS OF STRATIFIED CARE IN THE MANAGEMENT OF MIGRAINE Rapoport A1, Lipton RB2, Williams P3, Sawyer J4, 1New England Center for Headache, Stamford, CT, USA; 2Albert Einstein College of Medicine and Innovative Medical Research, New York, NY, USA; 3Genesis Pharma Strategies, Beaconsfield, UK; 4AstraZeneca, Macclesfield, UK
PMH9	A MANAGED CARE VALIDATION PROGRAM FOR A PHARMACOECONOMIC MODEL OF MAJOR DEPRESSION Casciano J1, Arikian S12, Doyle JJ12, Casciano R1, 1The Analytica Group Ltd., New York, NY, USA; 2Columbia University, School of Public Health, New York, NY, USA
PMH10	A MODEL TO PERFORM ECONOMIC EVALUATIONS OF INTERVENTIONS FOR ACUTE MUSCULAR LOW BACK PAIN Neighbors D1, Earnshaw SR1, Bell L1, Bhattacharyya SK2, 1Research Triangle Institute, Research Triangle Park, NC, USA; 2Procter and Gamble Pharmaceuticals, Mason, OH, USA
PMH11	TREATMENT GUIDELINES COMPARED TO CLINICAL PRACTICE FOR ACUTE MUSCULAR LOW BACK PAIN Earnshaw SR1, Neighbors D1, Bell L1, Bhattacharyya SK2, 1Research Triangle Institute, Research Triangle Park, NC, USA; 2Procter and Gamble, Mason, OH, USA
PMH12	THE EFFICIENCY OF DRUG TREATMENT IN FIRST EPISODE SCHIZOPHRENIA: TREATMENT GUIDELINES IN THE UK Davies LM1, Lewis S2, 1Centre for Health Economics, University of York, York, UK; 2School of Psychiatry and Behavioural Sciences, University of Manchester, Manchester, UK
PMH12	VALIDATION OF ANTIDEPRESSANT UTILIZATION RATES IN THE PACIFIC NORTHWEST Fehr AF1, Hutchins DS1, McFarland BH2, Young CH1, Signa BF1, 1PCS Health Systems, Inc., Scottsdale, AZ, USA; 2Oregon Health Sciences University, Portland, OR, USA
PMH14	USE OF OLANZAPINE AND RISPERIDONE AT BASELINE IN A PROSPECTIVE STUDY OF THE COURSE OF TREATMENT FOR SCHIZOPHRENIA Johnstone BM1, Dulisse BK2, Loosbrock DL1, Gibson PJ1, 1Health Outcomes Evaluation Group, Eli Lilly and Company, Indianapolis, IN, USA; 2Statistical and Mathematical Sciences, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
PMH15	UTILIZATION OF ANTIPSYCHOTIC MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIA IN A MANAGED CARE POPULATION Nichol MB1, Harada ASM1, Jones JP1, McCombs JS1, Grogg A2, Gilderman A3, Vaccaro J4, 1Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA, USA; 2Janssen Pharmaceutica, West Trenton, NJ, USA; 3Prescription Solutions, Costa Mesa, CA, USA; 4PacifiCare Behavioral Health, Inc., Van Nuys, CA, USA
PMH16	USE OF ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN A VETERANS POPULATION Hudson T, Feng W, Owen R, Austen M, Veterans Administration, North Little Rock, AR, USA
PMH17	BIPOLAR DISORDER DRUG USE PATTERNS AND COMPLIANCE IN MEDI-CAL POPULATION Li J1, McCombs J1, Stimmel G2, 1Department of Pharmaceutical Economic and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA; 2Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
PMH18	USE OF NONBARBITURATE SEDATIVE/HYPNOTIC AGENTS IN AN AMBULATORY POPULATION Hornquist M1, Carlson A2, Morris L3, 1University of Minnesota, College of Pharmacy, Minneapolis, MN, USA; 2Data Intelligence, LLC, Eden Prairie, MN, USA; 3IMS Health, Plymouth Meeting, PA, USA
PMH19	ANTIPSYCHOTIC DRUG USE PATTERNS AND THE COST OF TREATING SCHIZOPHRENIA: DATA FROM THE MEDICAID PROGRAMS OF ALABAMA, GEORGIA, KENTUCKY, AND MICHIGAN Lyu RR1, McCombs JS1, Johnstone BM2, Muse DN3, 1Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA; 2Health Outcomes Evaluation Group, Eli Lilly and Company, Indianapolis, IN, USA; 3Donald N. Muse and Associates, Washington, DC, USA
PMH20	MEDICAL RESOURCES CONSUMPTION BY PATIENTS WITH CHRONIC AND BREAKTHROUGH PAIN Noe L1, Peeples P2, 1Ovation Research Group, Highland Park, IL, USA; 2ALZA Pharmaceuticals, Mountain View, CA, USA
PMH21	COMMUNITY PHARMACIST ASSESSMENT OF THE QUALITY OF LIFE OF TREATED AMBULATORY DEPRESSED PATIENTS Taylor AT12, Longe RL12, Spruill WJ1, Wade WE1, Wagner PJ2, 1University of Georgia, Athens, GA, USA; 2Medical College of Georgia, Augusta, GA, USA
PMH22	CAN THE BRIEF "QOLWM" DISCRIMINATE AMONG MIGRAINEURS IN THE COMMUNITY? Cramer JA1, Silberstein S2, Winner P 3, Chmiel J4, Noble K4, 1Yale School of Medicine, New Haven, CT, USA; 2Jefferson Headache Center, Philadelphia, PA, USA; 3Palm Beach Headache Center, West Palm Beach, FL, USA; 4Abbott Laboratories, Abbott Park, IL, USA
PMH23	HOW MUCH CHANGE IN QUALITY OF LIFE AND SYMPTOM SCORES REPRESENTS A DETECTABLE DIFFERENCE FOR SCHIZOPHRENIA PATIENTS? Cramer JA2, Rosenheck R12, 1VA Connecticut Healthcare System, New Haven, CT, USA; 2Yale University School of Medicine, New Haven, CT, USA
PMH24	TRANSLATIONS OF THE MIGRAINE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE (MSQ): A PSYCHOMETRIC COMPARISON BETWEEN THE ENGLISH, FINNISH, DUTCH, HUNGARIAN, AND SPANISH TRANSLATIONS Grossman PR, Black LK, Kwong J, Glaxo Wellcome Inc., Research Triangle Park, NC, USA
PMH25	THE IMPACT OF SCHIZOPHRENIA ON HEALTH-RELATED QUALITY OF LIFE (HRQL) FOR PATIENTS ADMITTED TO PSYCHIATRIC UNITS OF GENERAL ACUTE CARE HOSPITALS Durkin MB1, Edell WS2, Mody SH1, Adams BE2, Repp EA2, 1Janssen Pharmaceutica, Titusville, NJ, USA; 2Mental Health Outcomes, Lewisville, TX, USA
PMH26	CHANGE IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA TAKING ANTIPSYCHOTIC AGENTS Edell WS1, Durkin MB2, Mody SH2, Adams BE1, White RE2, Qiu AZ1, 1Mental Health Outcomes, Lewisville, TX, USA; 2Janssen Pharmaceutica, Titusville, NJ, USA
PMH27	THE IMPACT OF DEPRESSION ON HEALTH-RELATED QUALITY OF LIFE (HRQL) Mody SH1, Edell WS2, Durkin MB1, Adams BE2, Repp EA2, 1Janssen Pharmaceutica, Titusville, NJ, USA; 2Mental Health Outcomes, Lewisville, TX, USA
PMH28	QUALITY OF LIFE DIFFERENCES BETWEEN PATIENTS WITH EPISODIC AND TRANSFORMED MIGRAINE Meletiche DM1, Lofland JH1, Young WB2, Hopkins MM2, 1Office of Health Policy and Clinical Outcomes, Thomas Jefferson University, Philadelphia, PA, USA; 2Jefferson Headache Clinic, Thomas Jefferson University Hospital, Philadelphia, PA, USA
PMH29	THE IMPACT OF AN OVER-THE-COUNTER MIGRAINE MEDICATION ON PATIENT QUALITY OF LIFE Burk C1, Nichol MB1, Wu Q1, Gilderman A2, Salas J2, 1University of Southern California, Los Angeles, CA, USA; 2Prescription Solutions, Costa Mesa, CA, USA
PMH30	MODELING LENGTH OF PRESCRIPTION THERAPY FOR DEPRESSION PATIENTS Billingsley J-K, Nichols JL, IMS Health, Plymouth Meeting, PA, USA
PMH31	TREATMENT OF CHILDHOOD DEPRESSION IN A MANAGED CARE POPULATION McLaughlin T1, Yazdani C1, Hansen J1, Margraf T2, 1NDC Health Information Services, Phoenix, AZ, USA; 2Pharmetrics, Inc., Boston, MA, USA
PMH32	QUANTIFYING THE ECONOMIC IMPACT OF POTENTIAL DRUG INTERACTIONS IN THE TREATMENT OF DEPRESSION Bourne MJ1, Prescott JD1, Baumann JA2, Mayo KW2, Bailey KL2, 1Practice Patterns Science, Inc., Saint Louis, MO, USA; 2Pharmacia & Upjohn, Inc., Peapack, NJ, USA
PMH33	NEUROLEPTIC DRUG EXPOSURE AND TARDIVE DYSKINESIA: A RECORDS-BASED CASE-CONTROL STUDY Marshall DL1, Hazlet TK2, Gardner JS2, Blough DK2, 1Marshall Pharmacy Outcomes Research Associates, Renton, WA, USA; 2University of Washington, Seattle, WA, USA
PMH34	CHARACTERIZATION AND ASSESSMENT OF DEPRESSION IN A CHRONIC NON-MALIGNANT PAIN POPULATION USING TWO DIFFERENT METHODOLOGIES IN A CLAIMS DATABASE Mody SH1, Hsu AY2, Dodd SL1, 1Janssen Pharmaceutica, Titusville, NJ, USA; 2Janssen Research Foundation, Titusville, NJ, USA
PMH35	ECONOMIC OUTCOMES WITH NEWER ANTIDEPRESSANTS FOR THE TREATMENT OF DEPRESSION IN A COMMERCIALLY-INSURED POPULATION Mukherjee R, Lian J, Hines P, Dezii C, Chen S, Scull R, Alter C, Bristol-Myers Squibb Company, Plainsboro, NJ, USA
PMH36	CONFORMANCE WITH ANTIPSYCHOTIC DRUG THERAPY GUIDELINES FOR TREATING SCHIZOPHRENIA IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM Luo M, McCombs JS, Shi L, Stimmel GL, University of Southern California, Los Angeles, CA, USA
PMH37	EVALUATING HEALTHCARE RESOURCE UTILIZATION IN A POPULATION OF MIGRIANE PATIENTS USING SUMATRIPTAN AND NON-SUMATRIPTAN PHARMACEUTICALS Joish VN1, Cady PS2, Culbertson VL2, Delate T1, 1College of Pharmacy, University of Arizona, Tucson, AZ, USA; 2College of Pharmacy, Idaho State University, Pocatello, ID, USA
PMH38	RESPONSE TO NEFAZODONE, CBASP, AND COMBINED THERAPY: IMPLICATIONS FOR CHRONIC DEPRESSION SEVERITY, FUNCTIONAL STATUS AND ECONOMIC OUTCOMES Crown WH1, Berndt E2, Finkelstein S2, Russell J3, Ling D1, White A1, Koran L4, Dunner D5, Kocsis J6, Kornstein S7, Borian F8, 1The MEDSTAT Group, Cambridge, MA, USA; 2Massachusetts Institute of Technology, Cambridge, MA, USA; 3University of Texas Medical Branch, Galveston, TX, USA; 4Stanford University School of Medicine, Stanford, CA, USA; 5University of Washington, Seattle, WA, USA; 6Cornell University Medical College, New York, NY, USA; 7Medical College of Virginia, Richmond, VA, USA; 8Bristol-Myers Squibb Company, Plainsboro, NJ, USA
PMH39	HEALTH CARE BURDEN AND COST OF PARKINSON'S DISEASE Wilson L1, Huang J2, Doshi D3, 1Pharmaceutical Policy and Economics, University of California, San Francisco, CA, USA; 2School of Pharmacy, University of California, San Francisco, CA, USA; 3SmithKline Beecham, Philadelphia, PA, USA
PMH40	ACCESS TO NEW MEDICATIONS TO TREAT SCHIZOPHRENIA Mark T, Dirani R, Russo P, The MEDSTAT Group, Inc., Washington, DC, USA
PMH41	PATTERNS OF ANTIDEPRESSANT USE AND CONCOMITANT PSYCHOTHERAPEUTIC AGENTS Fulop G1, Bona JR2, Brookler R1, Nemeroff CB2, 1Merck-Medco Managed Care, LLC, Franklin Lakes, NJ, USA; 2Emory University, School of Medicine, Atlanta, Georgia, USA
PMH42	THE IMPACT OF ADDING SSRI ANTIDEPRESSANTS TO THE MEDCAID FORMULARY IN CALIFORNIA McCombs JS, Shi L, Stimmel G, Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
OSTEOPOROSIS RESEARCH
POS1	THE BURDEN OF OSTEOPOROSIS TO THE STATE OF FLORIDA: PROJECTIONS FOR 2000 - 2010 Burge RT, Worley D, Procter & Gamble Pharmaceuticals, Cincinnati, OH, USA
POS2	INTEREST OF THE SIMPLE CALCULATED OSTEOPOROSIS RISK ESTIMATION (SCORE) TOOL FOR A MORE RATIONAL USE OF BONE DENSITOMETRY BenSedrine W1, Devogelaer JP2, Kaufman JM3, Goemaere S3, Depresseux G2, Bruyere O1, Reginster JY1, 1WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders - Department of Epidemiology and Public Health, University of Liège, Liège, Belgium; 2Department of Rheumatology, University Hospital St Luc, Brussels, Belgium; 3Department of Endocrinolology, University Hospital Gent, Gent, Belgium
POS3	THE SIMPLE CALCULATED OSTEOPOROSIS RISK ESTIMATION (SCORE) DOES NOT ALLOW TO IDENTIFY BELGIAN WOMEN WITH A HIGH RISK OF OSTEOPOROSIS BenSedrine W1, Devogelaer JP2, Kaufman JM3, Goemaere S3, Depresseux G2, Bruyere O1, Reginster JY1, 1WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders - Department of Epidemiology and Public Health, University of Liège, Liège, Belgium; 2Department of Rheumatology, University Hospital St Luc, Brussels, Belgium; 3Department of Endocrinolology, University Hospital Gent, Gent, Belgium
POS4	COST-EFFECTIVENESS OF SCREENING FOR OSTEOPOROSIS IN ELDERLY WOMEN Du HV, Hay J, University of Southern California, School of Pharmacy, Los Angeles, CA, USA
POS5	PREVALENCE OF PHARMACOTHERAPY FOR THE TREATMENT AND PREVENTION OF OSTEOPOROS IN A MANAGED CARE ENVIRONMENT Hall J, Nelson M, Ingenix International, Eden Prairie, MN, USA
ARTHRITIS RESEARCH
PAR1	THE BURDEN OF EARLY RHEUMATOID ARTHRITIS ON HEALTH RELATED QUALITY OF LIFE Kosinski M1, Wanke LA2, Buatti MC3, 1QualityMetric, Inc., Lincoln, RI, USA; 2Immunex Corporation, Seattle, WA, USA; 3Wyeth-Ayerst Laboratories, Philadelphia, PA, USA
PAR2	PHARMACOECONOMICAL ANALYSIS OF NON-STEROID ANTI-INFLAMMATORY DRUGS IN RHEUMATOLOGY Nasonova VA1, Vorobjov PA2, Tsvetkova ES1, Avksentieva MV2, 1Institute of Rheumatology, Moscow, Russia; 2Moscow Medical Academy, Moscow, Russia
PAR3	REDUCED UTILIZATION OF ANTIULCERANT DRUGS WITH CELECOXIB: FINDINGS OF THE PAINLESS TRIAL Castaldo RS1, Luke DR2, Grisanti MW3, Kalmuk E4, Palazzo RG5, LaDuca RL5, 1Buffalo Managed Care, Buffalo, NY, USA; 2Medical Division, Pfizer Inc., Ledyard, CT, USA; 3Buffalo Rheumatology, Buffalo, NY, USA; 4Sister Hospitals, Cheektowaga, NY, USA; 5Promedicus, Hamburg, NY, USA
PAR4	NSAID UTILIZATION AMONG COMMERCIALLY INSURED MEMBERS IN A MANAGED CARE ENVIRONMENT Hall J, Clouse J, Ingenix International, Eden Prairie, MN, USA
PAR5	COMPARING THE HEALTH RELATED QUALITY OF LIFE OUTCOMES OF TREATMENT FOR EARLY RHEUMATOID ARTHRITIS Bury-Maynard D1, Kosinski M1, Wanke LA2, Buatti MC3, 1QualityMetric, Inc., Lincoln, RI, USA; 2Immunex Corporation, Seattle, WA, USA; 3Wyeth-Ayerst Laboratories, Philadelphia, PA, USA
PAR6	QUALITY OF LIFE MEASUREMENTS AS PREDICTORS OF CHANGE IN THERAPY IN PATIENTS WITH MUSCULOSKELETAL DISORDERS Yazdani C1, Cox ER2, Castro WLR3, 1NDC Health Information Services, Phoenix, AZ, USA; 2School of Pharmacy, University of Arizona, Tucson, AZ, USA; 3School of Medicine, University of Arizona, Tucson, AZ, USA
PAR7	THE LONGTERM SAFETY AND EFFECTIVENESS OF CYCLOSPORINE IN PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS (RA) Marra CA1, Guh D1, Fisher JH2, Chalmers A2, Esdaile J2, Anis AH1, 1CHEOS, St. Paul's Hospital, Vancouver, BC, Canada; 2Mary Pack Arthritis Centre, Vancouver, BC, Canada
WOMEN'S & MEN'S HEALTH DISORDERS RESEARCH
PMW1	THE NEED FOR A QUALITY-OF-LIFE INSTRUMENT FOR ERECTILE DYSFUNCTION: A SYSTEMATIC REVIEW OF THE LITERATURE Lenderking WR12, Sweeney SL2, Pashos CL12, Flanders SC3, 1Abt Associates Clinical Trails, Cambridge, MA, USA; 2Harvard Medical School, Boston, MA, USA; 3TAP Holdings Inc., Deerfield, IL, USA
PMW2	DOES TESTOSTERONE AFFECT HEALTH-RELATED QUALITY OF LIFE IN HEALTHY, ELDERLY MALES? - A PILOT STUDY Reddy P1, White CM1, Dunn AB2, Moyna NM3, Thompson PD3, 1Pharmacy School, University of Connecticut, Storrs, CT, USA; 2Pharmacy School, Northeastern University, Boston, MA, USA; 3Cardiology Department, Hartford Hospital, Hartford, CT, USA
PMW3	PRESCRIPTION DRUG USE DURING PREGNANCY: A CLAIMS ANALYSIS Zenk HA1, Carlson A2, 1College of Pharmacy, University of Minnesota, Minneapolis, MN, USA; 2Data Intelligence, LLC, Eden Prairie, MN, USA
PMW4	MEASUREMENT PROPERTIES OF QUALITY OF LIFE INSTRUMENTS IN ERECTILE DYSFUNCTION (ED): A REVIEW OF PUBLISHED RESULTS Emery MP1, Kunle A1, Marquis P2, Sagnier PP3, Kubin M3, 1Mapi Research Institute, Lyon, France; 2Mapi Values, Lyon, France; 3Bayer, Slough, UK
PMW5	A PHARMACOECONOMIC EVALUATION OF HORMONE REPLACEMENT THERAPY IN THE UNITED KINGDOM AND BELGIUM Doyle JJ13, Arikian S13, Casciano J1, Casciano R1, Baleeva J2, Gonzalez MA1, 1The Analytica Group Ltd., New York, NY, USA; 2Wyeth-Ayerst Laboratories, St. Davids, PA, USA; 3Columbia University, School of Public Health, New York, NY, USA
PMW6	MATCHING VA UROLOGISTS' PREFERENCES IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA WITH CLINICAL PRACTICE GUIDELINES Fernandes AW1, Amonkar MM1, Madhavan S1, Nseyo UO2, 1School of Pharmacy, West Virginia University, Morgantown, WV, USA; 2Virginia Commonwealth University, Richmond, VA, USA
ECONOMIC AND OUTCOMES RESEARCH METHODOLOGICAL ISSUES
PMT1	THE VALUE OF OBSERVATIONAL DATASETS IN THE ECONOMIC EVALUATION OF PHARMACEUTICALS: UK OBSERVATIONS Tolley K1, Pang F2, Brown M1, 1Outcomes Research, Pfizer Central Research, Sandwich, Kent, UK; 2Centre for Health Economics, University of York, York, UK
PMT2	RELIABILITY OF PRESCRIPTION CLAIMS DATA FOR HEALTH CARE RESEARCH Thomas J1, Hutchins DS2, Fehr AF2, Mitrany D2, 1Purdue University, West Lafayette, IN, USA; 2PCS Health Systems, Inc., Scottsdale, AZ, USA
PMT3	PREDICTING DRUG SPENDING: UPDATE AND EVALUATION OF A REVISED CHRONIC DISEASE SCORE Zhao Z, Boscarino JA, Deverka PA, Epstein RS, Wang Chin J, Merck-Medco Managed Care, LLC, Franklin Lakes, NJ, USA
PMT4	METHODOLOGICAL ISSUES IN ESTIMATING DISEASE PROGRESSION: IS MARKOV MODEL THE BEST METHOD? Shih YCT1, Ke XT2, 1MEDTAP International, Bethesda, MD, USA; 2Department of Health Services Research and Management, Texas Tech University, Health Sciences Center, Lubbock, TX, USA
PMT5	DEVELOPMENT OF MULTI-LANGUAGE PATIENT OUTCOME ASSESSMENTS Rentz AM1, Trudeau E2, Schmier JK1, Dubois D3, Jones R4, Marquis P2, Willian MK4, Revicki DA1, 1Center for Health Outcomes Research, MEDTAP International, Bethesda, MD, USA; 2MAPI Research Institute, Lyon, France; 3Janssen Pharmaceutica, Beerse, Belgium; 4Janssen Pharmaceutica, Titusville, NJ, USA
PMT6	MONITORING THE GATEKEEPER: METHODOLOGIES FOR THE DEVELOPMENT OF PROCESS AND OUTCOME MEASURES FOR THE EVALUATION OF IRBS Gold KF12, 1Abt Associates, Bethesda, MD, USA; 2Georgetown University, Department of Biostatistics, Washington, DC, USA
PMT7	THE FRENCH HEALTH UTILITIES INDEX MARK 3 Le Galès C1, Buron C1, Costet N1, Rosman S1, Slama G2, 1INSERM, Le Kremlin Bicétre, France; 2Service d’Endocrinologie et Maladies Metaboliques-diabetologiques, Hotel-Dieu, Paris, France
PMT8	DEVELOPMENT OF A NEW SCORING OF THE WOMEN'S HEALTH QUESTIONNAIRE (WHQ) Girod I1, Keininger D2, de la Loge C1, Hunter M3, 1Mapi Values, Lyon, France; 2Mapi Research Institute, Lyon, France; 3Department of Psychology, St Thomas' Hospital, London, UK
PMT9	ASSESSING THE COST-EFFECTIVENESS RATIO OF A NEW ANTI-PLATELET AGENT: METHODOLOGIC ISSUES Levy E1, Gabriel S2, Dinet J2, Carita P2, 1Université Paris IX Dauphine, Paris, France; 2Health Economics & Outcome Research Department, Sanofi-Synthelabo, Bagneux, France
PMT10	MODELLING ISSUES: FIRST EPISODE SCHIZOPHRENIA Davies LM1, Lewis S2, 1Centre for Health Economics, University of York, York, UK; 2School of Psychiatry and Behavioural Sciences, University of Manchester, Manchester, UK
PMT11	METHODOLOGY FOR IDENTIFYING PATIENTS AT HIGH RISK FOR OSTEOPOROTIC FRACTURES WITHIN A MANAGED CARE ENVIRONMENT Heaton AH, Littlefield RS, Martin SL, Prime Therapeutics Inc., Eagan, MN, USA
PMT12	DATA REQUIREMENTS OF SECOND-GENERATION ECONOMIC MODELS IN HIV/AIDS Simpson KN1, Voit EO2, Hutton J3, Sun Eugene4, Ashraf T4, 1Center for Health Care Research, Medical University of South Carolina, Charleston, SC, USA; 2Department of Biometry and Epidemiology, Medical University of South Carolina, Charleston, SC, USA; 3MEDTAP International, London, UK; 4Abbott Laboratories, Abbot Park, IL, USA
PMT13	TRANSFERING THE RESULTS FROM ECONOMIC EVALUATIONS: THE USE OF BASILIXIMAB IN TRANSPLANT PATIENTS Lee KM1, Coyle D1, Baladi JF2, 1Clinical Epidemiology Unit, Loeb Health Research Institute, Ottawa, ON, Canada; 2Novartis Canada Inc., Montreal, QC, Canada
PMT14	IMPROVING THE EVIDENCE BASE OF ECONOMIC ANALYSES Coyle D, Lee KM, Clinical Epidemiology Unit, Loeb Health Research Institute, Ottawa Hospital, Ottawa, ON, Canada
PMT15	VALIDATION OF FRAMINGHAM REGRESSION EQUATIONS FOR LOCAL USE Milne RJ12, 1Health Outcomes Associates Ltd., Auckland, New Zealand; 2University of Auckland, Auckland, New Zealand
PMT16	ESTIMATION OF ANNUAL CARDIOVASCULAR RISK IN PILOTS Milne RJ12, 1Health Outcomes Associates Ltd., Auckland, New Zealand; 2University of Auckland, Auckland, New Zealand
PMT17	DEALING WITH SKEWED DATA: AN EXAMPLE USING ASTHMA-RELATED COSTS OF MEDICAID CLIENTS Rascati KL, Smith MJ, The University of Texas, College of Pharmacy, Austin, TX, USA
PMT18	BIAS ARISING FROM MISSING DATA IN A RETROSPECTIVE STUDY OF THE OUTCOMES OF INTRA-ABDOMINAL INFECTIONS Davey P1, Libby G1, Hunter K1, Broomhall J1, Kosteridis D1, Steinke D1, Yin D2, 1Medicines Monitoring Unit, Ninewells Hospital, Dundee, Scotland; 2Merck & Co., White Plains, NJ, USA
PMT19	NON-RANDOMIZED STUDIES COMPARING OLANZAPINE AND RISPERIDONE: BASELINE SIMILARITIES AND DIFFERENCES Gibson PJ, Loosbrock DL, Health Outcomes Evaluation Group, Eli Lilly and Company, Indianapolis, IN, USA
PMT20	THE USE OF ECONOMIC ANALYSES IN PRACTICE GUIDELINE DEVELOPMENT Wallace JF1, Ofman JJ1, Hohlbauch AA1, Lewensztain LS1, Richards MS2, Henning JM2, Weingarten SR1, 1Zynx Health, Inc., Cedars-Sinai, Department of Health Services Research, Beverly Hills, CA, USA; 2TAP Holdings, Inc., Deerfield, IL, USA
PMT21	DERIVING HEALTH UTILITIES FROM EFFICACY OUTCOME SCALES IN ALZHEIMER'S DISEASE (AD) Lanctôt KL12, Oh PI12, Risebrough N1, Mazzotta P1, 1Health Outcomes and PharmacoEconomics (HOPE) Research Centre, Sunnybrook and Women's College Health Sciences Centre, Toronto, ON, Canada; 2University of Toronto, Toronto, ON, Canada
PMT22	TREATMENT SATISFACTION IN OUTCOMES RESEARCH: AN OVERVIEW OF STUDY MEASURES Wang AY, Graham LA, Copley-Merriman C, Outcomes Research Department, Parke-Davis Pharmaceutical Research, Ann Arbor, MI, USA
PMT23	MONTE-CARLO SIMULATION AS AN ALTERNATIVE TECHNIQUE IN ADDRESSING THE UNIT COST VARIABILITY ISSUE Tran G1, McKenna M1, Kennedy L1, Pang F, 1The Lewin Group, Bracknell, UK; 2Centre for Health Economics, University of York, York, UK
PMT24	'CAMOUFLAGED SAMPLING' USING BC MINISTRY OF HEALTH DATA; A METHOD OF RECRUITING SUBJECTS WHILE PRESERVING DATA PRIVACY Maclure M1, Lynd LD1, Warren LD1, Pare PD2, Anis AH23, 1Pharmacare, BC Ministry of Health, Victoria, BC, Canada; 2University of British Columbia, Department of Health Care and Epidemiology, Vancouver, BC, Canada; 3Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, BC, Canada
PMT25	COMPARATIVE ECONOMETRIC MODELS OF MEDICAL COSTS Wu Q, Hay JW, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA, USA
PMT26	FIELLER'S INTERVAL, ITS EXTENSIONS AND THEIR APPLICATIONS IN COST-EFFECTIVENESS ANALYSES Jiang GJ1, Williams GR1, Wu J2, 1Knoll Pharmaceutical Company, Mount Olive, NJ, USA; 2Marquette University, Milwaukee, WI, USA
PMT27	PHARMACOGENOMICS: EVALUATING THE ECONOMIC IMPACT Veenstra DL, Higashi MK, University of Washington, Seattle, WA, USA
PMT28	HEALTH RELATED QUALITY OF LIFE IN A GENERAL SWEDISH POPULATION WITH A GENDER PERSPECTIVE Lundberg L1, Bardage C1, Johannesson M2, Bingefors K13, Isacson D1, 1Department of Pharmacy, Pharmaceutical Services Research, Uppsala University, Uppsala, Sweden; 2Centre for Health Economics, Stockholm School of Economics, Stockholm, Sweden; 3Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden
PMT29	THE INFLUENCE OF STATISTICAL ERRORS ON THE COST EFFECTIVENESS OF TREATMENTS FOLLOWING A PHASE-III CLINICAL TRIAL Kamae I1, Yanagisawa S12, 1Graduate School of Medicine, Kobe University, Kobe, Japan; 2Crecon Research and Consulting Inc., Tokyo, Japan
PMT30	PREFERENCE BASED INDEX FROM THE SF-12 Sengupta N, Nichol MB, Globe D, Pharmaceutical Economics & Policy, University of Southern California, Los Angeles, CA, USA
PMT31	AN ASSESSMENT OF COST-UTILITY OF PATIENTS FROM SF-36 SCORES USING THE BEAVER DAM HEALTH OUTCOMES STUDY METHOD Nadesan B, Cady P, Culbertson V, College of Pharmacy, Idaho State University, Pocatello, ID, USA
PMT32	UTILITY ESTIMATION USING THE EQ-5D: EXPERT PANEL DATA AND ALTERNATIVE METHODS OF SYNTHESIS Smith D12, Davies L1, Manca A1, Kind P1, 1Centre for Health Economics, University of York, York, UK; 2The University of Washington, School of Pharmacy, Seattle, WA, USA
PMT33	LINGUISTIC VALIDATION OF THE VASCULAR QUALITY OF LIFE QUESTIONNAIRE (VASCUQOL) IN 8 LANGUAGES Conway K1, Uzun V1, Girod I2, Morgan M3, Koch P4, 1Mapi Research Institute, Lyon, France; 2Mapi Values, Lyon, France; 3Lewisham Hospital, London, UK; 4Boehringer Ingelheim, Ingelheim, Germany
PMT34	ASSESSING PHYSICIAN PRACTICE PROFITABILITY USING AN ACTIVITY BASED COSTING MODEL Stephens JM, Bell CF, Klingman D, PAREXEL International, Outcomes Research Group, Alexandria, VA, USA
PMT35	VALUING NON-WORKPLACE PRODUCTIVITY LOST IN MIGRAINEURS: HUMAN CAPITAL APPROACH AND REPLACEMENT COST METHOD Kim SS, Lofland JH, Office of Health Policy and Clinical Outcomes at Thomas Jefferson University Hospital, Philadelphia, PA, USA
PMT36	LINGUISTIC VALIDATION OF THE WORK LIMITATIONS QUESTIONNAIRE (WLQ) Conway K1, Mear I1, Touzet L1, Lerner D2, Bresnahan B3, Martens L3, 1Mapi Research Institute, Lyon, France; 2The Health Institute, Boston, USA; 3ICOM Health Economics, Raritan, NJ, USA
PMT37	BENEFITS OF EARLY MODELING IN DRUG DISCOVERY Stevenson M1, Bryant-Comstock L2, Brennan A1, 1School of Health and Related Research, University of Sheffield, Sheffield, UK; 2Glaxo Wellcome Inc., Research Triangle Park, NC, USA
WILLINGNESS-TO-PAY & WORK PERFORMANCE RESEARCH
PWP1	COMPARATIVE BURDEN OF ILLNESS AT TWO LARGE U.S. COMPANIES Wogen S1, Birnbaum HG2, Greenberg PE2, Holland MD2, Deverka P1, Epstein R1, 1Merck-Medco Managed Care, Franklin Lakes, NJ, USA; 2Analysis Group/Economics, Cambridge, MA, USA
PWP2	A METHODOLOGY TO MEASURE PRODUCTIVITY OF HEALTH OUTCOMES GROUPS Sesti AM, Abright J, McLaughlin-Miley C, Copley-Merriman C, Parke-Davis Pharmaceutical Research, Ann Arbor, MI, USA
PWP3	CONSUMER PREFERENCES FOR DENTAL ANESTHESIA: PUTTING YOUR MONEY WHERE YOUR MOUTH IS Matthews D1, Rocchi A2, Garni A3, 1Dalhousie University, Halifax, NS, Canada; 2Axia Research, Hamilton, ON, Canada; 3McMaster University, Hamilton, ON, Canada
PWP4	A WILLINGNESS-TO-PAY ASSESSMENT OF TWO TREATMENTS FOR OBESITY Trakas K12, Oh PI12, Shear NH12, 1University of Toronto, Toronto, ON, Canada; 2HOPE Research Centre, Sunnybrook and Women's College Health Sciences Centre, Toronto, ON, Canada
PWP5	WORK PRODUCTIVITY EFFECTS OF DIABETES: IMPLICATIONS FOR RESEARCH AND POLICY Lavigne JE, University of Rochester School of Medicine & Dentistry, Rochester, NY, USA
PWP6	A PRELIMINARY STUDY OF PROVISION OF PHARMACEUTICAL CARE IN COMMUNITY PHARMACY IN SINGAPORE: COST ANALYSIS & PATIENT WILLINGNESS TO PAY Li SC, Chan SY, How PPC, Department of Pharmacy, National University of Singapore, Crescent, Singapore